Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RPA1 | P27694 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381168 | 0.95 | CYP1A2 (0.44) | CYP1A2POLBRPA1SMN1; SMN2THRB | |
| SCHEMBL24928463 | 0.90 | POLB (0.46) | CYP1A2POLBRPA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19044281 | 0.81 | CYP1A2 (0.49) | CYP1A2POLBSMN1; SMN2THRBALDH1A1 | |
| SCHEMBL1423019 | 0.77 | HTR2A (0.40) | ALOX15TSHRHIF1A | |
| SCHEMBL6381453 | 0.74 | ALDH1A1 (0.42) | CYP1A2SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL13424047 | 0.74 | CYP1A2 (0.48) | CYP1A2ALDH1A1 | |
| SCHEMBL1423651 | 0.72 | HTR2A (0.44) | — | |
| SCHEMBL15009288 | 0.72 | CDC7 (0.54) | POLBRPA1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23980136 | 0.72 | POLB (0.52) | CYP1A2POLBRPA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13423899 | 0.72 | CYP1A2 (0.41) | CYP1A2ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025029075-A1 | NOVEL BIPHENYL DERIVATIVE AS PD-L1 INHIBITOR | (주)아이랩 | 2025-02-06 | — | — | WO | disclosed |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023086319-A1 | 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| CN-113429410-B | Polyheterocyclic substituted pyrimidine or pyridylamine derivatives, compositions and medical uses thereof | 上海海雁医药科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-113429410-A | Polyheterocyclic substituted pyrimidine or pyridylamine derivatives, compositions and medical uses thereof | 上海海雁医药科技有限公司 | 2021-09-24 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| EP-2350084-B1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | CCNK, CDK1, CDKN1A | CYP1A2 1673/4885POLB 2660/4885RPA1 2332/4885 |
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | CYP1A2 679/4885POLB 995/4885RPA1 3762/4885 |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | CYP1A2 957/4885POLB 3091/4885RPA1 4669/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CYP1A2 3220/4885POLB 1228/4885RPA1 2923/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | CYP1A2 2476/4885POLB 3571/4885RPA1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.